![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Bioequivalence of a Fixed-Dose Combination of
Rilpivirine/Emtricitabine/Tenofovir Alafenamide to
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Rilpivirine
|
|
|
Reported by Jules Levin
15th European AIDS Conference, October 21-24, 2015, Barcelona, Spain
Julia Zack, Eileen Doyle, Hiba Graham, Mona Vimal, Steve West, Erin Quirk
Gilead Sciences, Inc., Foster City, California, USA
![EACS1.gif](../images/110515/110515-8/EACS1.gif)
![EACS2.gif](../images/110515/110515-8/EACS2.gif)
![EACS3.gif](../images/110515/110515-8/EACS3.gif)
![EACS4.gif](../images/110515/110515-8/EACS4.gif)
![EACS5.gif](../images/110515/110515-8/EACS5.gif)
![EACS6.gif](../images/110515/110515-8/EACS6.gif)
![EACS7.gif](../images/110515/110515-8/EACS7.gif)
![EACS8.gif](../images/110515/110515-8/EACS8.gif)
![EACS9.gif](../images/110515/110515-8/EACS9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|